Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2013 Jul;123(7):2764-72. doi: 10.1172/JCI67227. Epub 2013 Jul 1.

AMPK, insulin resistance, and the metabolic syndrome.

Author information

1
Diabetes and Metabolism Research Unit, Boston University School of Medicine, Boston, Massachusetts 02118, USA. nrude@bu.edu

Abstract

Insulin resistance (IR) and hyperinsulinemia are hallmarks of the metabolic syndrome, as are central adiposity, dyslipidemia, and a predisposition to type 2 diabetes, atherosclerotic cardiovascular disease, hypertension, and certain cancers. Regular exercise and calorie restriction have long been known to increase insulin sensitivity and decrease the prevalence of these disorders. The subsequent identification of AMP-activated protein kinase (AMPK) and its activation by exercise and fuel deprivation have led to studies of the effects of AMPK on both IR and metabolic syndrome-related diseases. In this review, we evaluate this body of literature, with special emphasis on the hypothesis that dysregulation of AMPK is both a pathogenic factor for these disorders in humans and a target for their prevention and therapy.

PMID:
23863634
PMCID:
PMC3696539
DOI:
10.1172/JCI67227
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center